The Tg.AC (v-Ha-ras) transgenic mouse model provides a reporter phenotype of skin papillomas in response to either genotoxic or nongenotoxic carcinogens. In common with the conventional bioassay, the Tg.AC model responds to known human carcinogens and does not respond to noncarcinogens. It also does not respond to most chemicals that are positive in conventional bioassays principally at sites of high spontaneous tumor incidence. The mechanism of response of the Tg.AC model is related to the structure and genomic position of the transgene and the induction of transgene expression through specific mediated interactions between the chemicals and target cells in the skin.
Ashby J., Tennant RW (1991). Defi nitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicals tested by the U.S. NTP . Mut Res257: 229—306.
2.
Blanchard KT, Ball DJ, Holden HE, Furst SM, Stoltz JH, Stoll RE (1998). Dermal carcinogenicity in transgenic mice: Relative responsiveness of male and female hemizygous and homozygous Tg.AC mice to 12-0-tetradecanoylphorbol 13-acetate (TPA) and benzene. Toxicol Pathol26: 541—547.
3.
Bos JL (1998). All in the family? New insights and questions regarding interconnectivity of Ras, Rap1, and Ral. EMBO J17: 6776—6782.
4.
Cannon RE, Spalding JW, Trempus CS, Szczesniak CJ, Virgil KM, Humble MC, Tennant RW (1997). Kinetics of wound-induced v-Ha-ras transgene expression and papilloma development in transgenic Tg.AC mice. Mol Carcinog20: 108—114.
5.
CannonRE, Graves S., Spalding JW, Trempus CS, TennantRW (2000). Oral administration of dimethylvinyl chloride increases frequency of forestomach papillomas in Tg.AC mice. Mol Carcinog29: 229—235.
6.
Dunson D., Haseman J., vanBirgelen A., Stasiewicz S., Tennant RW (2000). Statistical analysis of skintumor data fromTg.AC mousebioassays. Toxicol Sci55: 293—302.
7.
Eastin W., Haseman J., Mahler J., Bucher J. (1998). The National Toxicology Program evaluation of genetically altered mice as predictive models for identifying carcinogens . Toxicol Pathol26: 461—473.
8.
Germolec DR, Spalding J., Yu HS, Chen GS, Simeonova PP, Humble MC, Bruccoleri A., Boorman GA, Foley JF, YoshidaT., Luster MI (1998). Arsenic enhancement of skin neoplasia by chronic stimulation of growth factors. Am J Pathol153:1775—1785.
9.
Goelz MF, Mahler J., Harry J., Myers P., Clark J., Thigpen JE, Forsythe DB (1998). Neuropathologic fi ndings associated with seizures in FVB mice. Lab Anim Sci48: 34—37.
10.
Hansen LA, Trempus CS, Mahler JF, Tennant RW (1996). Association of tumor development with increased cellular proliferation and transgene over-expression but not c-Ha-ras mutations , in v-Ha-ras transgenic Tg.AC mice. Carcinogenesis17: 1825—1833.
11.
Haseman JK, Hailey, JR, Morris RW (1998). Spontaneous neoplasm incidences in Fischer 344 rats and B6C3F1 mice in two-year carcinogenicity studies: A National Toxicology Program update. Toxicol Pathol26: 428— 441.
12.
Holden H., Stoll R., Spalding J., Tennant R. (1998). Hemizygous Tg.AC transgenic mouse as a potential alternative to the two-year mouse carcinogenicity bioassay: Evaluation of husbandry and housing factors. J ofAppl Toxicol18: 19—24.
13.
Humble MC, Kouprina N., Noskov VN, Graves J., Garner E., Tennant RW, Resnick MA, Larionov V., Cannon RE (2000). Radial transformation-associated recombination cloning from the mouse genome: Isolation of Tg.AC transgene with fl anking DNAs. Genomics70: 292—299.
14.
Leder A., Kuo A., Cardiff R., Sinn E., Leder P. (1990). v-Ha-ras transgene abrogates the initiation step in mouse skintumorigenesis: Effects of phorbol esters and retinoic acid. Proc Natl Acad Sci USA87: 9178—9182.
15.
Mahler JF, Stokes W., Mann PC, Takaoka M., Maronpot RR (1996). Spontaneous lesions in aging FVB/N mice. Toxicol Pathol24: 710—716.
16.
Mahler J., Flagler N., Malarkey D., Mann P., Haseman J., Eastin W. (1998). Spontaneous and chemically induced proliferative lesions in Tg.AC transgenic and p53-heterozygous mice. Toxicol Pathol26: 501—511.
17.
Maronpot RR , Fox T., Malarkey DE, Goldsworthy T. (1995). Mutations in the ras proto-oncogene: Clues to etiology and molecular pathogenesis of mouse liver tumors. Toxicology101: 125—156.
18.
NTP (1990). Toxicology and carcinogenesis studies of glycidol (CAS No. 556-52-5) in F344/N rats and B6C3F 1 mice (gavage studies). National Toxicology Program , Research Triangle Park, North Carolina. Technical Report No. 374.
19.
Robinson D. (1998). The International Life Sciences Institute's role in the evaluation of alternative methodologies for the assessment of carcinogenic risk. Toxicol Pathol26: 474—475.
20.
Sanders JM, BurkaLT, Chanas B., Matthews HB (2001). Comparative xenobiotic metabolism between Tg.AC and p53 +/- genetically altered mice and the respective wildtypes. Toxicol Sci (in press).
21.
Slaga TJ, Fischer SM (1983). Strain differences and solventeffects in mouse skin carcinogenesis experiments using carcinogens, tumor initiators and promoters . Prog Exp Tumor Res26: 85—109.
22.
Spalding JW , Momma J., Elwell MR, Tennant RW (1993). Chemically induced skin carcinogenesis in a transgenic mouse line (Tg.AC) carrying a v-Ha-ras gene . Carcinogenesis14: 1335—1341.
23.
Spalding JW , French JE, Tice RR, Furedi-Machacek M., Haseman JK, Tennant RW (1999). Development of a transgenic mouse model for carcinogenesis bioassays: Evaluation of chemically induced skin tumors in Tg.AC mice. Toxicol Sci49: 241—254.
24.
Spalding J. , French J., Stasiewicz S., Furedi-Machacek M., Conner F., Tice R., Tennant R. (2000). Responses of transgenic mouse lines p53(defi cient) and Tg.AC to agents tested in conventional carcinogenicity bioassays . Toxicol Sci53:213—223.
25.
TennantRW, French JE, Spalding JW (1995). Identifying chemical carcinogens and assessing potential risk in short-term bioassays using transgenic mouse models. Environ Health Perspect103: 942—950.
26.
Tennant RW, Stasiewicz S., Mennear J., French JE, Spalding JW (1999). Genetically altered mouse models for identifying carcinogens. In: The Use of Short- and Medium-term Tests for Carcinogens and Data on Genetic and Related Effects in Carcinogenic Hazard Evaluation, McGregor D, Rice J, Venitt S (eds). IARC, Lyon, France, pp 123—150.
27.
Thompson K. , Rosenzweig B., Sistare F. (1998). An evaluation of the hemizygous transgenic Tg.AC mouse for carcinogenicity testing of pharmaceuticals. II. A genotypic marker that predicts tumorigenic responsiveness. Toxicol Pathol26: 548—555.
28.
Trempus C., Mahler J., Ananthaswamy H., Loughlin S., Tennant R., French J. (1998). Photocarcinogenesis and susceptibility to UV radiation in the v-Ha-ras transgenic Tg.AC mouse. J Invest Dermatol111: 445—451.
29.
Van Duuren BL , Langseth L., Goldschmidt BM, Orris L. (1967). Carcinogenicity of epoxides, lactones, and peroxy compounds. VI. Structure and carcinogenic activity. J Nat Cancer Inst39: 1217—1228.
30.
Vainio H., Wilbourn J. (1993). Cancer etiology: Agents causally associated with human cancer. Pharmacol and Toxicol72: Supplement 1, S4—S11.
31.
Weaver J., Contrera J., Rosenzweig B., Thompson K., Faustino P., Strong J., Ellison C., Anderson L., Prasanna H., Long-Bradley P., Lin K., Zhang J., Sistare F. (1998). An evaluation of the hemizygous transgenic Tg.AC mouse for carcinogenicity testing of pharmaceuticals. I. Evidence for a confounding nonresponder phenotype. Toxicol Pathol26: 532—540.
32.
Wright J., Hansen L., Mahler J., Szczesniak C., Spalding J. (1995). Odontogenic tumors in the v-Ha-ras (Tg.AC) transgenic mouse. Arch Oral Biol40: 631—638.
